Tramadol: Discovery, Development, Safety and Pharmacovigilance
Tramadol occupies an unusual position among opioid analgesics. It combines opioid-receptor activity with monoaminergic actions, while a genetically variable metabolic pathway produces an active metabolite with stronger mu-opioid activity. This creates a practical paradox: the same prescribed dose may yield insufficient analgesia in one patient and dangerous opioid toxicity in another. Yet genetic variability is only one component of risk; interacting medicines, renal function, dose escalation, patient age, concomitant sedatives and treatment duration may matter just as much. [1–4]
- Tramadol: Discovery, Development, Safety and Pharmacovigilance
- Discovery and commercial development
- Pharmacokinetics, pharmacogenetics and interactions
- Evidence for analgesia and its limitations
- The evolving safety profile
- Product-specific listedness: United States and European Union
- Practical pharmacovigilance: from case to signal
- Governance and quality review
- Key takeaways
- References
- Regulatory Note
Discovery and commercial development
Origins and first authorisations
Tramadol was developed by the German pharmaceutical company Grünenthal and entered clinical use in Europe before its 1995 US approval. The original chemistry is traceable to early-1960s Grünenthal patent filings. A 2024 stereochemistry and patent-history review identifies Kurt Flick and Ernst Frankus in the early patent family, while the American Chemical Society traces the marketed substance to a 1965 British patent and a 1977 Tramal launch. These sources support a company-led discovery history, but patent inventorship, compound synthesis, product launch and marketing authorisation are different milestones and should not be collapsed into a single 'invention date'. [9,10]
A particularly important distinction concerns stereochemistry: the early patent family described cis/trans mixtures, whereas marketed tramadol hydrochloride is the cis racemate. The review reports a German authorisation dated 19 June 1980 and notes Grünenthal's statement of a 1977 commercial launch; these dates are not necessarily contradictory because the events described differ. The same review identifies UK authorisation of Zydol capsules in April 1994 and the US Ultram tablet approval on 3 March 1995. The FDA's contemporaneous Ultracet administrative record independently confirms March 1995 approval of Ultram. [9,11]
The commercial lifecycle subsequently broadened from immediate-release products to extended-release formulations and numerous generic presentations. The INN tramadol denotes the active substance; a product's salt, strength, release technology and route remain essential to medication reconciliation and regulatory assessment. A fixed combination containing tramadol must not be used as a surrogate for the safety denominator of tramadol monotherapy. Historical national authorisations and current labels are separate evidence: a formulation approved in one jurisdiction does not establish identical indications or paediatric eligibility elsewhere.
Why the pharmacology was distinctive
Tramadol is administered as a racemic mixture. The parent molecule has comparatively weak mu-opioid receptor affinity and also inhibits neuronal reuptake of noradrenaline and serotonin. Its O-desmethyl metabolite, often called M1, has greater mu-opioid receptor affinity and contributes importantly to analgesia and opioid adverse effects. This is not a simple prodrug model in which the parent is inactive: parent and metabolite contribute different pharmacological effects. [1,3]
This dual mechanism matters clinically. A seizure or serotonin syndrome may involve the parent drug, an interacting serotonergic medicine, or both, while respiratory depression may be amplified by increased opioid activity of M1 and concurrent central nervous system depressants. A report that attributes all toxicities solely to the opioid receptor would miss the monoaminergic component. Conversely, the fact that tramadol has monoaminergic activity does not make it a suitable antidepressant or negate its dependence potential.
Pharmacokinetics, pharmacogenetics and interactions
CYP2D6 is a variable metabolic gate
CYP2D6 catalyses an important O-demethylation step to M1. A human phenotyping study demonstrated substantially different O-demethylation in poor versus extensive metabolisers, supporting the biological relevance of the polymorphism. Subsequent postoperative clinical work examined how CYP2D6 genotype relates to analgesic response. These studies support a mechanistic and clinical association; they do not permit accurate prediction of every individual's pain control from genotype alone. [3,4]
Reduced CYP2D6 activity can lower M1 formation and reduce opioid-mediated analgesia. Ultrarapid metabolism may increase M1 exposure and respiratory-depression risk. An inhibitor of CYP2D6 can functionally alter metabolism even without a genetic poor-metaboliser phenotype. The US label highlights a particularly important time-dependent interaction: after a CYP2D6 inhibitor is stopped, M1 may increase while parent tramadol decreases, changing the balance of efficacy and toxicity. [1]
CYP3A4 interactions add a second layer. Introducing an inhibitor, stopping an inducer, or changing several interacting drugs together can alter parent exposure and downstream metabolite formation. This is not safely summarised as 'all enzyme inhibitors increase opioid effect'. The relevant direction depends on which enzyme is affected, the timing and the balance between parent and active metabolite. A useful medication history therefore records start, stop and dose-change dates, not merely a list of drugs present at the time of the event. [1]
Renal and hepatic function
Both impaired clearance and changes in metabolic formation can affect tramadol exposure. Renal or hepatic dysfunction is especially important in older patients and in cases involving sedation, confusion or seizures. The specific dosage and interval recommendations must be taken from the actual immediate-release or extended-release product label; they should not be transferred between formulations without verification. The French 50-mg capsule SmPC explicitly discusses delayed elimination and possible extension of the dosing interval in renal or hepatic impairment. [2]
A causal map, not a deterministic algorithm
The useful mental model is a three-way interaction among dose and formulation, metabolic capacity and drug interactions, and patient susceptibility. A CYP2D6 result is evidence about one pathway, not a complete adverse-event causality determination. A reported genotype should be accompanied by laboratory methodology, inferred phenotype where available, co-medications, exposure dates and clinical course. Without those details, 'poor metaboliser' can become a misleading shorthand for an otherwise unexplained therapeutic failure.
Evidence for analgesia and its limitations
Tramadol's clinical development addressed moderate to moderately severe pain in different acute and chronic settings. The 2026 US immediate-release label retains historical chronic nonmalignant-pain trial data, including an exposure cohort of 550 patients and a cumulative adverse-reaction table for 427 participants. The table is an adverse-reaction summary, not a modern proof of sustained net benefit in every chronic-pain population. [1]
Interpreting analgesic trials requires attention to pain indication, comparator, dose, rescue medication, duration, discontinuation, functional outcomes and adverse-event ascertainment. Short-term improvement in a selected trial cannot establish that long-term opioid exposure is preferable to non-opioid alternatives for a patient whose pain mechanism and comorbidities differ. Current US labelling restricts opioid use to situations in which alternative treatments are inadequate and emphasises individualised assessment and risk mitigation. [1]
The pharmacovigilance perspective is broader than efficacy versus placebo. It asks whether a clinically meaningful benefit persists while patients remain exposed to dependence, respiratory depression, falls, interactions, withdrawal and potentially inappropriate escalation. Patients who discontinue early for toxicity contribute less later exposure time; comparing crude event proportions across studies without handling discontinuation can therefore be misleading.
What controlled evidence says about chronic osteoarthritis pain
Tramadol's historical authorisation and clinical familiarity should not be mistaken for a large, durable effect on pain-related function. The 2019 Cochrane review of tramadol for osteoarthritis included 22 studies, involving 3,871 tramadol-treated participants and 2,625 comparators across studies of roughly one week to three months. Compared with placebo, tramadol alone produced about a four-point mean pain improvement on a 100-point scale, while adverse-event withdrawals were more frequent. The review judged that average improvements in pain and function were probably not clinically important for most patients. Its conclusions apply to the osteoarthritis populations and short observation windows studied, not to all acute postoperative pain indications. [5]
A later network meta-analysis focused on six randomised knee/hip osteoarthritis trials involving 3,611 participants. It found dose-related pain-score differences versus placebo but only a small functional advantage at 300 mg/day, alongside increased gastrointestinal and central nervous system adverse events and withdrawals. The authors cautioned against assuming that statistically significant pain-score changes translate into a favourable overall benefit-risk balance. These two reviews are overlapping syntheses, not independent cohorts to add together. [6]
| Evidence source | Population and horizon | Main benefit-risk interpretation | Important limitation |
|---|---|---|---|
| Historical USPI trial summaries [1] | Selected chronic nonmalignant-pain trial participants | Describes exposure and cumulative adverse reactions | Not a contemporary comparative effectiveness estimate |
| Cochrane 2019 [5] | Osteoarthritis; trials generally no longer than three months | Small average benefit, more withdrawals for adverse effects | Does not establish long-term outcomes or other pain indications |
| Network meta-analysis 2021 [6] | Knee/hip osteoarthritis; six RCTs | Dose-dependent pain effect with increasing tolerability burden | Indirect dose comparisons and selected trial populations |
For pharmacovigilance, this evidence highlights a longitudinal question: when adverse reactions drive early discontinuation, analyses restricted to continuing users can obscure the true tolerability burden. A defensible benefit-risk narrative should therefore report both symptom outcomes and discontinuation, with indication, formulation, duration and concomitant therapy clearly specified.
Pharmacogenetic guidance versus product authorisation
The Clinical Pharmacogenetics Implementation Consortium (CPIC) 2021 opioid guideline recommends avoiding tramadol in CYP2D6 poor metabolisers because of likely inadequate M1-mediated analgesia and in ultrarapid metabolisers because of possible severe toxicity. For intermediate metabolisers, it advises ordinary label-based initial dosing with attention to inadequate response and an alternative analgesic when warranted. These are genotype-informed therapeutic recommendations, not new indications, regulatory contraindications or a requirement to genotype every recipient. [7]
The Dutch Pharmacogenetics Working Group separately classifies CYP2D6 testing for tramadol as potentially beneficial and suitable for individual consideration; its phenotype-based recommendations differ in some details from CPIC. Both guidance sets must be read in their own context, including any later updates, and neither substitutes for the current local product information. [8] For a suspected pharmacogenetic adverse reaction, record the test method and diplotype, inferred phenotype, interacting inhibitors, dosing history and clinical observations. A genotype alone cannot establish a specific patient's causal attribution.
The evolving safety profile
Respiratory depression, sedation and overdose
Respiratory depression is the most immediately life-threatening opioid toxicity. Risk may be increased at treatment initiation, after dose escalation, with sedatives such as benzodiazepines, in patients with respiratory disease, and when metabolism or clearance changes. The US product label carries prominent opioid safety warnings and includes special precautions for children and for CYP2D6 ultrarapid metabolism. A report of a sleeping or unresponsive patient requires clinical assessment of respiratory rate, oxygenation, consciousness, co-ingestants, timing and any administered rescue therapy; the word 'sedation' alone is insufficient to establish respiratory depression. [1]
In overdose, tramadol can produce both opioid toxicity and seizures. This combination complicates emergency management and case interpretation. The French SmPC describes respiratory depression, convulsions and coma among overdose manifestations and notes that haemodialysis alone is not an adequate detoxification strategy. The clinical response is urgent supportive management under appropriate emergency protocols, not a retrospective pharmacovigilance exercise. [2]
Seizures and serotonin syndrome
Seizures have been reported within recommended tramadol doses, with additional risk when doses exceed recommendations or other medicines lower seizure threshold. Clinical follow-up should document witnessed semiology, previous epilepsy, metabolic triggers, substance exposure, antidepressants and antipsychotics, dosage and timing. A seizure temporally associated with tramadol is important even if another plausible cause exists; causality should be recorded with its uncertainty rather than forced into a binary verdict. [1,2]
Serotonin syndrome is a potentially life-threatening clinical syndrome with neuromuscular, autonomic and mental-status features. It is not synonymous with nausea, tremor or agitation in isolation. The US label and French SmPC identify serotonergic co-medications as important interaction risks, and the French section 4.8 lists serotonin syndrome with frequency not known. A case should record clonus, hyperreflexia, temperature, muscle tone, timing and serotonergic drug changes, while considering infection, withdrawal, anticholinergic toxicity and other mimics. [1,2]
The pharmacological connection to antidepressants makes cross-article reconciliation useful: existing QPPV articles on venlafaxine, sertraline and duloxetine discuss serotonergic interactions. The tramadol article adds the opioid-metabolite and respiratory-depression dimensions rather than reproducing those antidepressant monographs.
Dependence, withdrawal and hyperalgesia
Tramadol is an opioid with addiction, misuse, physical dependence and withdrawal risks. Dependence can occur during therapeutic use; it is not proof of misuse. Abrupt discontinuation after sustained exposure can produce withdrawal symptoms, while a deterioration in pain may reflect progression of the original condition, withdrawal-associated symptoms or opioid-induced hyperalgesia. The US label discusses opioid-induced hyperalgesia and allodynia and provides instructions for safe reduction or discontinuation. [1]
The safety assessor should avoid describing a patient as 'drug-seeking' without source evidence. Record objective prescribing and dispensing history, duration, tolerance, escalating dose, functional response, attempts at reduction, withdrawal phenotype and any documented substance-use disorder. A clinician's decision to taper is not itself evidence that the original prescription was inappropriate.
Hypoglycaemia, hyponatraemia and other less obvious risks
The April 2026 US label includes specific warning sections for hyponatraemia and hypoglycaemia. Hypoglycaemia has been reported with tramadol, sometimes requiring hospitalisation, often in patients with additional risk factors such as diabetes, renal insufficiency or older age. These observations justify investigation, not a claim that tramadol caused every low glucose value recorded during exposure. [1]
For suspected hypoglycaemia, collect glucose measurement, symptoms, timing, antidiabetic treatment, food intake, renal function, infection and response to treatment changes. For suspected hyponatraemia, record sodium trends, fluid status, concurrent diuretics or serotonergic drugs and relevant endocrine or renal disorders. Seriousness, causality and listedness must be assessed independently.
Pregnancy, lactation and paediatric exposure
Maternal opioid exposure may affect the fetus or neonate, including neonatal opioid withdrawal with prolonged use. The US label warns about serious risks in children and does not support extrapolating adult pain data to paediatric use. It advises against breastfeeding during treatment because of potential infant exposure and serious reactions. [1]
The French 50-mg capsule SmPC has its own age restrictions, including a statement that this presentation is not suitable for children younger than 15 years. That is not equivalent to a universal European age rule for all tramadol presentations. A maternal or paediatric case requires exact product, gestational or postnatal timing, dose, duration, breastfeeding details and infant findings. [2]
Product-specific listedness: United States and European Union
Precisely identified documents
US: Unichem Pharmaceuticals (USA), Inc., tramadol hydrochloride film-coated immediate-release oral tablets, DailyMed set ID 007bf37f-0e46-426a-ac8c-be63d4b7414c, version 26, DailyMed page updated 10 April 2026; assessed 8 November 2026. The document provides sections 5, 6.1, 6.2, 7 and 8. It is a specific generic tablet label, not a claim about every US tramadol formulation. [1]
EU member state: French ANSM product information for TRAMADOL HCS 50 mg, gélule, immediate-release oral capsule, French RCP updated 19 March 2025, accessed 8 November 2026; section 4.8 contains the adverse-reaction frequency table. The French public database itself shows a later site-level update of 3 November 2026; this must not be confused with the RCP revision date. This nationally authorised French product is an EU member-state SmPC, not a centrally authorised EMA product or a UK SmPC. [2]
Listed terms and different presentation of frequency
| Safety concept | US Unichem immediate-release tablet | French ANSM 50-mg capsule |
|---|---|---|
| Nausea | Section 6.1 cumulative trial table: 24% by day 7, 40% by day 90, specified N=427 | Section 4.8: very common |
| Dizziness | Section 6.1 dizziness/vertigo: 26% by day 7, 33% by day 90 | Section 4.8: very common |
| Constipation | Section 6.1: 24% by day 7, 46% by day 90 | Section 4.8: common |
| Seizure | Sections 5.10 and 6.1, including uncommon/postmarketing grouping | Section 4.8: rare epileptiform convulsions |
| Serotonin syndrome | Sections 5.9 and 6.1, including uncommon/postmarketing grouping | Section 4.8: frequency not known |
| Respiratory depression | Dedicated warning; clinical and postmarketing context | Section 4.8: rare |
| Hypoglycaemia | Section 5.21 warning and section 6.2 postmarketing | Section 4.8: frequency not known |
The US figures are cumulative incidence in a particular historical clinical-study population, not cross-sectional incidence, population risk or the same frequency system used in France. The US label's less-than-1% grouping explicitly mixes trial and postmarketing material; it cannot be interpreted as a precise incidence estimate for serotonin syndrome or seizures. The French categories are regulatory frequency classifications for its specific product. These are different presentations of safety evidence, not contradictory estimates. [1,2]
Section-level verification and interpretation (9 November 2026)
The comparison was rechecked against the identified source documents on 9 November 2026. The US DailyMed record identifies Unichem as packager, immediate-release film-coated tablets, version 26, updated 10 April 2026; its prescribing information describes recent major changes in October 2025. The French public database identifies TRAMADOL HCS 50 mg capsules, marketing-authorisation holder HCS bvba, with RCP text revised 19 March 2025. The French database's 3 November 2026 site update is not the revision date of this particular RCP. [1,2]
For the French capsule, section 4.8 explicitly classifies nausea and dizziness as very common, constipation and somnolence as common, convulsions and respiratory depression as rare, and serotonin syndrome and hypoglycaemia as frequency not known. It also lists headache, vomiting, dry mouth, hyperhidrosis, fatigue and other reactions. The terms and frequency categories are specific to this SmPC and must not be transferred wholesale to another national product. [2]
For the US tablet, section 6.1 gives cumulative percentages for nausea, dizziness/vertigo and constipation from its defined clinical-study cohort; these are not estimates for all treated patients. Section 6.2 includes postmarketing reports of hypoglycaemia, while section 5.21 describes clinical precautions. The presence of a risk in section 5 alone does not establish that the identical term occurs in the trial adverse-reaction table. The US boxed warning addresses addiction, abuse and misuse, respiratory depression, accidental ingestion, sedative co-use, neonatal withdrawal and paediatric risks. [1]
The most defensible term-level conclusion is therefore listed in the named source at the cited section for the reactions above; the article does not assert that any omitted reaction is unlisted. For a real ICSR, document the applicable formulation, local label or designated reference safety information, effective version and coded event term before making an expectedness decision. Causality, seriousness, listedness and regulatory reporting remain distinct assessments.
What the comparison does and does not establish
The named terms above are documented in the respective public product information at the sections identified. The comparison is selective rather than a complete verbatim reconciliation of every term. It does not establish that an omitted reaction is unlisted, nor that a term in a US warning is necessarily a frequency-classified reaction in section 6.1. The exact case event and applicable reference safety information must be checked before a formal expectedness decision. Public USPI/SmPC listedness, company-core listedness, case causality and jurisdiction-specific reportability are distinct determinations.
A change in product presentation can change the safety context: a French immediate-release capsule and US immediate-release tablet have different authorised wording, even when the active moiety is the same. Extended-release tramadol and fixed combinations require separate product-specific label assessment for their own case records. When a company uses a defined reference safety information document for expectedness, that effective version and its authorised scope—not this teaching table—govern the operational decision.
Practical pharmacovigilance: from case to signal
Intake and chronology
A useful tramadol safety report begins with the exact product, formulation, dose, route, indication and timing. Record who administered it, whether it was prescribed, the number of doses actually taken, any dispensing or administration error, co-exposures, renal and hepatic function and the onset of each symptom. Preserve the reporter's original terms, then code medically supported concepts using the applicable terminology version. A report can be valid despite missing laboratory confirmation; missing confirmation should not be invented.
| Reported event | Essential follow-up | Important alternative explanations |
|---|---|---|
| Respiratory depression | Respiratory rate, oxygenation, consciousness, co-sedatives, naloxone response | Other opioids, pulmonary disease, neurological injury |
| Seizure | Witness account, timing, dose, glucose/sodium, EEG where available | Epilepsy, metabolic abnormality, withdrawal, interacting drugs |
| Serotonin syndrome | Clonus, hyperreflexia, temperature, serotonergic co-medications | Infection, other toxidromes, withdrawal |
| Hypoglycaemia | Measured glucose, symptoms, diabetes treatment, renal function | Insulin/sulfonylureas, poor intake, sepsis |
| Withdrawal | Treatment duration, last dose, taper history, symptom trajectory | Pain recurrence, anxiety disorder, other substance withdrawal |
| Loss of analgesia | Pain diagnosis, adherence, CYP2D6 inhibitors, phenotype if known | Disease progression, inadequate dosing, wrong pain mechanism |
An illustrative interaction case
A hypothetical adult treated with stable tramadol develops worsening pain after a new CYP2D6-inhibiting antidepressant is introduced. Increasing tramadol without considering the interaction could increase parent-drug exposure and monoaminergic toxicity without predictably restoring M1-mediated analgesia. Later stopping the inhibitor may change M1 formation again. The assessor should capture both medication changes, clinical timing, objective adverse effects and alternative causes of pain deterioration. This is a teaching scenario, not an actual case report or a recommendation to adjust treatment without clinical supervision. [1,3]
The same case may generate more than one reportable clinical concept: reduced effect, interaction, medication error if applicable, and a suspected adverse reaction. The correct coding and reporting treatment depends on the information actually received and the governing regulatory framework. Do not automatically classify lack of efficacy as a serious adverse reaction or infer a pharmacogenetic phenotype from response alone.
Aggregate signal evaluation
A rise in reports of tramadol-associated hypoglycaemia or seizures should trigger questions before causal conclusions: did the exposed population grow, did prescribing shift to older or renally impaired patients, did co-prescribing change, did a safety communication stimulate reporting, or did the case definition broaden? Spontaneous reporting counts cannot supply an incidence denominator. Review case narratives for objective confirmation, dechallenge, plausible alternatives, dose and interacting medicines; then seek appropriate comparative clinical or observational evidence.
A signal evaluation should document its question, inclusion criteria, duplicate handling, data lock point, observed pattern, limitations and proposed next step. A disproportionality measure may help prioritise review but is not itself a risk ratio or proof of causation. For a serious event, individual-case processing and any required regulatory reporting continue under applicable procedures while aggregate assessment proceeds.
Medication error and product quality interfaces
Tramadol's multiple strengths and release forms create opportunities for dosing confusion. A report involving a modified-release product taken incorrectly is not interchangeable with ordinary immediate-release exposure. Capture package, batch, strength, tablet or capsule identification, instructions, actual administration and whether the product was damaged or incorrectly labelled. Where a quality complaint coexists with an adverse event, reconcile the quality and safety investigations while preserving distinct responsibilities and source records.
Risk minimisation and effectiveness
The US label describes opioid-related safety precautions and a REMS framework; these are US product-regulatory conditions, not automatically EU obligations. The French RCP and national prescribing controls should be interpreted within their own legal jurisdiction. Operational controls may include medication reconciliation, attention to high-risk co-prescriptions, careful selection of patients, safe storage, education about overdose signs and appropriate taper planning. The precise mandatory actions must be taken from current local requirements and product conditions. [1,2]
Risk-minimisation effectiveness should be judged by relevant process and outcome evidence, not simply by the existence of educational material. Examples include whether interacting medications are identified before dispensing, whether high-risk patients receive appropriate review, whether dosing errors decline and whether severe events are recognised promptly. These are proposed evaluation measures, not invented inspection findings.
Governance and quality review
A traceable assessment should retain original source documents, follow-up attempts, medical review, case coding, product identification, effective reference label, causality reasoning, expectedness basis, submission history and signal decisions. Because tramadol can be encountered in medical information, poison-centre contacts, product complaints and partner channels, reconciliation across intake sources is important. The same case may be described differently by a clinician and patient; resolve duplicates without erasing clinically meaningful disagreement.
Key takeaways
Tramadol's safety cannot be understood as either a conventional opioid alone or an antidepressant-like drug alone. Parent and metabolite effects, CYP2D6 and CYP3A4 interactions, formulation, co-medication and patient vulnerability jointly shape the clinical picture. Respiratory depression, seizures, serotonin syndrome, dependence, withdrawal and less obvious metabolic events require differentiated case assessment. The US and French product documents both contain important safety information, but their trial frequencies, regulatory categories and presentation-specific scope cannot be collapsed into one universal listedness table.
References
- US National Library of Medicine, DailyMed. Unichem Pharmaceuticals (USA), Inc. Tramadol hydrochloride immediate-release film-coated tablets; set ID 007bf37f-0e46-426a-ac8c-be63d4b7414c, version 26. Page updated 10 April 2026. Sections 1, 5, 6, 7, 8, 12. Accessed 8 November 2026. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=007bf37f-0e46-426a-ac8c-be63d4b7414c&version=26
- Agence nationale de sécurité du médicament et des produits de santé (ANSM). TRAMADOL HCS 50 mg, gélule, Résumé des caractéristiques du produit; updated 19 March 2025. Sections 4.1–4.9. Accessed 8 November 2026. https://base-donnees-publique.medicaments.gouv.fr/medicament/60712486/extrait
- Paar WD, Poche S, Gerloff J, Dengler HJ. Polymorphic CYP2D6 mediates O-demethylation of the opioid analgesic tramadol. Eur J Clin Pharmacol. 1997;53:235–239. doi:10.1007/s002280050368. https://pubmed.ncbi.nlm.nih.gov/9476037/
-
Stamer UM, Lehnen K, Höthker F, et al. Impact of CYP2D6 genotype on postoperative tramadol analgesia. Pain. 2003;105:231–238. doi:10.1016/S0304-3959(03)00212-4. https://pubmed.ncbi.nlm.nih.gov/14499440/
-
Toupin April K, et al. Tramadol for osteoarthritis. Cochrane Database Syst Rev. 2019;5:CD005522. doi:10.1002/14651858.CD005522.pub3. https://www.cochrane.org/CD005522/MUSKEL_tramadol-osteoarthritis
- Zhang et al. Efficacy and safety of tramadol for knee or hip osteoarthritis: a systematic review and network meta-analysis of randomized controlled trials. Arthritis Care Res. 2023;75:158–165. doi:10.1002/acr.24750. https://pubmed.ncbi.nlm.nih.gov/34251756/
- Crews KR, et al. Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6, OPRM1, and COMT genotypes and select opioid therapy. Clin Pharmacol Ther. 2021;110:888–896. doi:10.1002/cpt.2149. https://ascpt.onlinelibrary.wiley.com/doi/10.1002/cpt.2149
-
Matic M, et al. Dutch Pharmacogenetics Working Group guideline for the gene–drug interaction between CYP2D6 and opioids (codeine, tramadol and oxycodone). Eur J Hum Genet. 2022;30:1105–1113. doi:10.1038/s41431-021-00920-y. https://pmc.ncbi.nlm.nih.gov/articles/PMC9553935/
-
Chiral Switches of Tramadol Hydrochloride, a Potential Psychedelic Drug—Past and Future. Pharmaceuticals. 2024. Patent-family analysis and historical product authorisations. https://pmc.ncbi.nlm.nih.gov/articles/PMC11403737/
- American Chemical Society. Molecule of the Week: Tramadol. 16 December 2014. Historical patent and Tramal launch chronology. https://www.acs.org/molecule-of-the-week/archive/t/tramadol.html
- US Food and Drug Administration. Ultracet NDA 21-123 administrative documents (2001), including contemporaneous reference to Ultram approval in March 1995. Historical regulatory record, not current tramadol product information. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21123_Ultracet_admindocs.pdf
Regulatory Note
This is an educational pharmacovigilance reference, not patient-specific prescribing advice or a substitute for the current authorised local product information. Regulatory status, product presentation and safety wording may change. Check the exact medicinal product, jurisdiction, revision date and applicable reference safety information when assessing a real case. Historical clinical-trial percentages and spontaneous-report data should not be interpreted as directly comparable incidence estimates.